aspartic acid has been researched along with Coronary Disease in 40 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (77.50) | 18.7374 |
| 1990's | 5 (12.50) | 18.2507 |
| 2000's | 3 (7.50) | 29.6817 |
| 2010's | 1 (2.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baumgartner, FJ | 1 |
| Barrio, JR | 1 |
| Henze, E | 1 |
| Schelbert, HR | 1 |
| MacDonald, NS | 1 |
| Phelps, ME | 1 |
| Kuhl, DE | 1 |
| Jelassi, A | 1 |
| Jguirim, I | 1 |
| Slimani, A | 1 |
| Najah, M | 1 |
| Hamda, KB | 1 |
| Addad, F | 1 |
| Hassine, M | 1 |
| Maatouk, F | 1 |
| Varret, M | 1 |
| Slimane, MN | 1 |
| Naber, CK | 1 |
| Baumgart, D | 1 |
| Heusch, G | 1 |
| Siffert, W | 1 |
| Oldenburg, O | 1 |
| Huesing, J | 1 |
| Erbel, R | 1 |
| Iakoubova, OA | 1 |
| Tong, CH | 1 |
| Chokkalingam, AP | 1 |
| Rowland, CM | 1 |
| Kirchgessner, TG | 1 |
| Louie, JZ | 1 |
| Ploughman, LM | 1 |
| Sabatine, MS | 1 |
| Campos, H | 1 |
| Catanese, JJ | 1 |
| Leong, DU | 1 |
| Young, BA | 1 |
| Lew, D | 1 |
| Tsuchihashi, Z | 1 |
| Luke, MM | 1 |
| Packard, CJ | 1 |
| Zerba, KE | 1 |
| Shaw, PM | 1 |
| Shepherd, J | 1 |
| Devlin, JJ | 1 |
| Sacks, FM | 1 |
| Bush, LR | 1 |
| Warren, S | 1 |
| Mesh, CL | 1 |
| Lucchesi, BR | 1 |
| Jiang, XR | 1 |
| Chen, WP | 1 |
| Shi, HL | 1 |
| Zhou, LF | 1 |
| Galiautdinov, GS | 1 |
| Liyou, N | 1 |
| Simons, L | 1 |
| Friedlander, Y | 1 |
| Simons, J | 1 |
| McCallum, J | 1 |
| O'Shaughnessy, K | 1 |
| Davis, D | 1 |
| Johnson, A | 1 |
| Nishiyama, Y | 1 |
| Nejima, J | 1 |
| Watanabe, A | 1 |
| Kotani, E | 1 |
| Sakai, N | 1 |
| Hatamochi, A | 1 |
| Shinkai, H | 1 |
| Kiuchi, K | 1 |
| Tamura, K | 1 |
| Shimada, T | 1 |
| Takano, T | 1 |
| Katayama, Y | 1 |
| Kühn, P | 2 |
| Probst, P | 2 |
| Rau, EE | 1 |
| Shine, KI | 1 |
| Gervais, A | 1 |
| Douglas, AM | 1 |
| Amos, EC | 1 |
| Döring, V | 1 |
| Bleese, N | 1 |
| Gercken, G | 1 |
| Kalmár, P | 1 |
| Lierse, W | 1 |
| Pokar, H | 1 |
| Rodewald, G | 1 |
| Marichal, A | 1 |
| Hess, W | 1 |
| Scheiber, G | 1 |
| Snaith, CD | 1 |
| Wright, G | 1 |
| Lofkin, M | 1 |
| Osbakken, M | 1 |
| Zhang, DN | 1 |
| Nelson, D | 1 |
| Erecińska, M | 1 |
| Pisarenko, OI | 3 |
| Oleĭnikov, OD | 1 |
| Shul'zhenko, VS | 1 |
| Studneva, IM | 3 |
| Kapel'ko, VI | 1 |
| Oleynikov, OD | 1 |
| Shulzhenko, VS | 1 |
| Ryff, IM | 1 |
| Kapelko, VI | 1 |
| Novikova, EB | 1 |
| Serebryakova, LI | 1 |
| Tskitishvili, OV | 1 |
| Ivanov, VE | 1 |
| Allen, BS | 5 |
| Okamoto, F | 5 |
| Buckberg, GD | 7 |
| Bugyi, H | 5 |
| Leaf, J | 5 |
| Young, H | 2 |
| Beyersdorf, F | 1 |
| Sjostrand, F | 1 |
| Maloney, JV | 1 |
| Schwaiger, M | 1 |
| Yeatman, L | 1 |
| Tillisch, J | 1 |
| Kawata, N | 1 |
| Messenger, J | 1 |
| Lee, C | 1 |
| Pisarenko, O | 1 |
| Studneva, I | 1 |
| Khlopkov, V | 1 |
| Solomatina, E | 1 |
| Ruuge, E | 1 |
| Vinten-Johansen, J | 2 |
| Rosenkranz, ER | 2 |
| Acar, C | 1 |
| Partington, M | 1 |
| Robertson, JM | 1 |
| Bugyi, HI | 1 |
| Nasseri, M | 1 |
| Bücherl, ES | 1 |
| Herbst, R | 1 |
| Szulc, EJ | 1 |
| Krüger, K | 1 |
| Lewandowicz, J | 1 |
| Wölke, F | 1 |
| Gavrilescu, S | 1 |
| Danciu, T | 1 |
| Fiat, F | 1 |
| Pop, T | 1 |
| Kopp, H | 1 |
| Simon, KH | 1 |
| Reichertz, PL | 1 |
| Noell, G | 1 |
| Hemmati, A | 1 |
| Nakane, M | 1 |
| Dockweiler, J | 1 |
| Fabris, C | 1 |
| Fanchiotti, GL | 1 |
| Barusco, G | 1 |
| Jaschke, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Study of Metabolic Intervention With Glutamate in Coronary Surgery II[NCT02592824] | Phase 3 | 321 participants (Actual) | Interventional | 2015-11-15 | Completed | ||
| Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827] | Phase 3 | 865 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Postoperative mortality was defined as mortality within 30 days of surgery. (NCT02592824)
Timeframe: up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 1 |
| Intravenous Saline Infusion | 6 |
suspected unexpected serious adverse reaction (NCT02592824)
Timeframe: within 24 hours from infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 0 |
| Intravenous Saline Infusion | 0 |
"Postoperative stroke was defined as neurological or cognitive deficit with a cerebral injury verified on (Computed Tomography) CT-scan. All suspected cases of stroke underwent CT-scan.~Stroke within 24 h of surgery was defined as a stroke that occurred within 24 h of surgery or signs of a stroke, when first assessable in deeply sedated patients on a ventilator." (NCT02592824)
Timeframe: within 24 hours from surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 0 |
| Intravenous Saline Infusion | 4 |
"Postoperative increase of NT-proBNP reflects postoperative myocardial dysfunction sustained in association with surgery. NT-proBNP usually peaks on the third to fourth postoperative day after coronary artery bypass surgery.~In the first GLUTAMICS trial a good agreement between hemodynamic criteria for postoperative heart failure and postoperative NT-proBNP was found." (NCT02592824)
Timeframe: from the day before surgery to the third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 5390 |
| Intravenous Saline Infusion | 6452 |
"Postoperative increase of NT-proBNP reflects postoperative myocardial dysfunction sustained in association with surgery. NT-proBNP usually peaks on the third to fourth postoperative day after coronary artery bypass surgery.~Previous observations suggest a blunted effect of glutamate in diabetic hearts." (NCT02592824)
Timeframe: from preoperative level to the third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 4503 |
| Intravenous Saline Infusion | 6825 |
Postoperative NT-proBNP reflects postoperative myocardial dysfunction. (NCT02592824)
Timeframe: first postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 4438 |
| Intravenous Saline Infusion | 4420 |
Postoperative NT-proBNP reflects postoperative myocardial dysfunction. (NCT02592824)
Timeframe: third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 8055 |
| Intravenous Saline Infusion | 8804 |
Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 147 |
| Saline Infusion | 152 |
ICU duration of stay (hours) (NCT00489827)
Timeframe: ICU stay
| Intervention | hours (Median) |
|---|---|
| Intravenous Glutamate | 21 |
| Saline Infusion | 21 |
(NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 31 |
| Saline Infusion | 25 |
Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 4 |
| Saline Infusion | 6 |
Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 1 |
| Saline Infusion | 5 |
maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days
| Intervention | µmol/L (Mean) |
|---|---|
| Intravenous Glutamate | 106 |
| Saline Infusion | 106 |
Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 3 |
| Saline Infusion | 16 |
p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative
| Intervention | µg/L (Median) | |
|---|---|---|
| CK-MB day 1 | Troponin-T day 3 | |
| Intravenous Glutamate | 14 | 0.27 |
| Saline Infusion | 14 | 0.24 |
Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU
| Intervention | percentage of saturated hemoglobin (Mean) | |
|---|---|---|
| SvO2 at weaning from CPB | SvO2 on arrival to ICU | |
| Intravenous Glutamate | 72.0 | 65.0 |
| Saline Infusion | 72.2 | 64.9 |
2 trials available for aspartic acid and Coronary Disease
| Article | Year |
|---|---|
[Hemodynamics of coronary surgery patients following magnesium aspartate infusion].
Topics: Aspartic Acid; Coronary Artery Bypass; Coronary Disease; Female; Hemodynamics; Humans; Male; Middle | 1992 |
[Clinical studies on the therapeutic effect of potassium-magnesium aspartate in coronary disease].
Topics: Adult; Aged; Aspartic Acid; Clinical Trials as Topic; Coronary Disease; Female; Humans; Magnesium; M | 1968 |
38 other studies available for aspartic acid and Coronary Disease
| Article | Year |
|---|---|
13N-labeled L-amino acids for in vivo assessment of local myocardial metabolism.
Topics: Amino Acids; Animals; Citric Acid Cycle; Coronary Disease; Dogs; Half-Life; Myocardium; Nitrogen Rad | 1981 |
[Association between variants of lipoprotein lipase and coronary heart disease in a Tunisian population].
Topics: Aged; Amino Acid Substitution; Asparagine; Aspartic Acid; Case-Control Studies; Coronary Disease; Fe | 2012 |
Role of the eNOS Glu298Asp variant on the GNB3825T allele dependent determination of alpha-adrenergic coronary constriction.
Topics: Adrenergic alpha-Agonists; Amino Acid Substitution; Aspartic Acid; Azepines; Blood Pressure; Coronar | 2003 |
Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS.
Topics: Alleles; Anticholesteremic Agents; Antigens, CD; Asparagine; Aspartic Acid; Coronary Disease; Geneti | 2006 |
Comparative effects of aspartate and glutamate during myocardial ischemia.
Topics: Animals; Aspartic Acid; Blood Pressure; Cats; Coronary Disease; Glutamates; Glutamic Acid; In Vitro | 1981 |
[Effect of potassium and magnesium aspartate on experimental myocardial ischemia and infarction].
Topics: Animals; Aspartic Acid; Cats; Coronary Disease; Female; Magnesium; Male; Myocardial Infarction; Pota | 1984 |
[Correction of nitrogen metabolic disorders in the myocardium in experimental ischemia].
Topics: Ammonia; Animals; Aspartic Acid; Coronary Disease; Dogs; Glutamates; Myocardium; Nitrogen; Time Fact | 1980 |
Coronary artery disease is not associated with the E298-->D variant of the constitutive, endothelial nitric oxide synthase gene.
Topics: Aspartic Acid; Case-Control Studies; Coronary Disease; Genotype; Glutamic Acid; Humans; Nitric Oxide | 1998 |
Ehlers-Danlos syndrome type IV with a unique point mutation in COL3A1 and familial phenotype of myocardial infarction without organic coronary stenosis.
Topics: Adult; Aneurysm; Aspartic Acid; Collagen; Coronary Disease; Ehlers-Danlos Syndrome; Emphysema; Glyci | 2001 |
[Hemodynamics and myocardial metabolism in coronary disease during beta receptor stimulation and administration of postassium magnesium aspartate (PMA)].
Topics: Adrenergic beta-Agonists; Aspartic Acid; Coronary Disease; Heart; Hemodynamics; Heptaminol; Humans; | 1975 |
[Effect of potassium-magnesium aspartate on hemodynamics and myocardial metabolism of coronary disease patient during beta receptor stimulation].
Topics: Acetoacetates; Adrenergic beta-Agonists; Angiography; Aspartic Acid; Blood Glucose; Blood Pressure; | 1975 |
Enhanced mechanical recovery of anoxic and ischemic myocardium by amino acid perfusion.
Topics: Amino Acids; Animals; Arginine; Aspartic Acid; Coronary Disease; Creatine; Glutamates; Hypoxia; Male | 1979 |
Enhanced mechanical recovery of anoxic and ischemic myocardium by amino acid perfusion.
Topics: Amino Acids; Animals; Arginine; Aspartic Acid; Coronary Disease; Creatine; Glutamates; Hypoxia; Male | 1979 |
Enhanced mechanical recovery of anoxic and ischemic myocardium by amino acid perfusion.
Topics: Amino Acids; Animals; Arginine; Aspartic Acid; Coronary Disease; Creatine; Glutamates; Hypoxia; Male | 1979 |
Enhanced mechanical recovery of anoxic and ischemic myocardium by amino acid perfusion.
Topics: Amino Acids; Animals; Arginine; Aspartic Acid; Coronary Disease; Creatine; Glutamates; Hypoxia; Male | 1979 |
[Metabolism and ultrastructure of magnesium aspartate-procaine arrested hearts of rabbit and man (author's transl)].
Topics: Adenine Nucleotides; Adenosine Triphosphate; Animals; Aspartic Acid; Coronary Disease; Glycogen; Hea | 1975 |
The effects of aspartate and 2-oxoglutarate upon glycolytic energy metabolites and mechanical recovery following global ischaemia in isolated rat hearts.
Topics: Adenine Nucleotides; Animals; Aspartic Acid; Coronary Disease; Glycolysis; In Vitro Techniques; Keto | 1992 |
Effect of cyclocreatine feeding on levels of amino acids in rat hearts before and after an ischemic episode.
Topics: Adenosine Triphosphate; Amino Acids; Animals; Aspartic Acid; Coronary Disease; Creatinine; Diet; Ene | 1991 |
[Relations of glutamate and aspartate contents of the heart and its energy state after ischemia].
Topics: Animals; Aspartic Acid; Coronary Disease; Energy Metabolism; Glutamates; Glutamic Acid; Guinea Pigs; | 1990 |
Association of myocardial glutamate and aspartate pool and functional recovery of postischemic heart.
Topics: Adenosine Triphosphate; Animals; Aspartic Acid; Coronary Disease; Creatine; Energy Metabolism; Gluta | 1989 |
Function and metabolism of dog heart in ischemia and in subsequent reperfusion: effect of exogenous glutamic acid.
Topics: Alanine; Ammonia; Animals; Aspartic Acid; Coronary Disease; Dogs; Female; Glutamates; Glutamic Acid; | 1985 |
Reperfusion conditions: critical importance of total ventricular decompression during regional reperfusion.
Topics: Animals; Aspartic Acid; Calcium; Cardiac Catheterization; Coronary Circulation; Coronary Disease; Di | 1986 |
Immediate functional recovery after six hours of regional ischemia by careful control of conditions of reperfusion and composition of reperfusate.
Topics: Animals; Aspartic Acid; Calcium; Citrates; Citric Acid; Coronary Circulation; Coronary Disease; Dogs | 1986 |
Early recovery of regional wall motion in patients following surgical revascularization after eight hours of acute coronary occlusion.
Topics: Aspartic Acid; Citrates; Citric Acid; Coronary Circulation; Coronary Disease; Glucose; Glutamates; G | 1986 |
An assessment of anaerobic metabolism during ischemia and reperfusion in isolated guinea pig heart.
Topics: Adenine Nucleotides; Anaerobiosis; Animals; Aspartic Acid; Citric Acid Cycle; Coronary Disease; Glut | 1988 |
Metabolic and histochemical benefits of regional blood cardioplegic reperfusion without cardiopulmonary bypass.
Topics: Animals; Aspartic Acid; Blood; Calcium; Cardiopulmonary Bypass; Coronary Circulation; Coronary Disea | 1986 |
Reperfusate composition: benefits of marked hypocalcemia and diltiazem on regional recovery.
Topics: Animals; Aspartic Acid; Benzazepines; Calcium; Coronary Circulation; Coronary Disease; Diltiazem; Do | 1986 |
Reperfusate composition: interaction of marked hyperglycemia and marked hyperosmolarity in allowing immediate contractile recovery after four hours of regional ischemia.
Topics: Animals; Aspartic Acid; Citrates; Citric Acid; Coenzymes; Coronary Circulation; Coronary Disease; Di | 1986 |
Safety of prolonged aortic clamping with blood cardioplegia. III. Aspartate enrichment of glutamate-blood cardioplegia in energy-depleted hearts after ischemic and reperfusion injury.
Topics: Animals; Aorta; Arterial Occlusive Diseases; Aspartic Acid; Coronary Disease; Dogs; Glutamates; Hear | 1986 |
[Practical experiences using procaine magnesium aspartate in open heart surgery].
Topics: Adolescent; Adult; Aspartic Acid; Biopsy; Child; Coronary Disease; Electrocardiography; Extracorpore | 1973 |
[Metabolic therapeutic possibilities of ischemic heart disease].
Topics: Angina Pectoris; Aspartic Acid; Coronary Disease; Electrocardiography; Female; Humans; Hypertension; | 1967 |
[Comparative studies on the action of the polarizing mixture and potassium-magnesium aspartate in the treatment of dysrhythmia in coronary disease].
Topics: Aged; Arrhythmias, Cardiac; Aspartic Acid; Coronary Disease; Humans | 1971 |
[Intravenous therapy of ischemic heart diseases by Tromcardin].
Topics: Adult; Aspartic Acid; Coronary Disease; Female; Humans; Injections, Intravenous; Magnesium; Male; Mi | 1969 |
Effect of potassium and tris-aspartate on heparin-induced serum free-fatty-acids evaluation, in man.
Topics: Aged; Arteriosclerosis; Aspartic Acid; Blood Glucose; Cholesterol; Coronary Disease; Fatty Acids, No | 1970 |
[Treatment of heart failure with Gladixol].
Topics: Aspartic Acid; Coronary Disease; Digitoxin; Diuretics; Female; Glomerulonephritis; Humans; Hypokalem | 1970 |
[Magnesium deficiency and cardiotherapy].
Topics: Aspartic Acid; Coronary Disease; Digoxin; Humans; Magnesium; Magnesium Deficiency; Potassium | 1971 |
[Therapy of disorders of myocardial metabolism with potassium-magnesium aspartate].
Topics: Adult; Aged; Aspartic Acid; Coronary Disease; Electrocardiography; Female; Heart Diseases; Humans; M | 1967 |
[Experimental study on the selective intracoronary infusion, with special reference to its effect on acute coronary stenosis].
Topics: Acute Disease; Animals; Aspartic Acid; Cardiac Catheterization; Cardiac Output; Coronary Disease; Co | 1968 |
[Treatment of coronary heart disease from the modern point of view].
Topics: Adult; Angina Pectoris; Animals; Aspartic Acid; Blood Circulation; Coronary Disease; Coronary Vessel | 1968 |
[On the mechanism of resumption of sinus rhythm in chronic atrial fibrillation. (Clinical contribution)].
Topics: Anesthesia, General; Aspartic Acid; Atrial Fibrillation; Coronary Disease; Electric Countershock; Hu | 1968 |
[Experience with the coronary therapeutic agent STENO-Tromcardin in the general practice].
Topics: Adult; Aspartic Acid; Coronary Disease; Female; Humans; Magnesium; Male; Methaqualone; Middle Aged; | 1969 |